報價延遲最少15分鐘:2025/07/17 16:42 EDT
盤後時段
|
||||
|
-- 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.41
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.30/-1.25
|
|
企業價值
22.40M
|
| 資產負債 |
|
每股賬面淨值
2.95
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
1.00M
|
|
每股收益
--
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/07/17 16:42 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product. |
